Key points from article :
MoglingBio, a privately held biotech company, completes its first seed investment.
Sole investor is venture capital firm Kizoo Technology Capital.
Company is developing new pharmacological approaches to rejuvenate old stem cells of the hematopoietic system.
Normalizing CDC42 activity can restore structure, order and functionality in those aged stem cells.
Underlying technology was developed over 15 years by its scientific co-founders, Prof. Yi Zheng and Prof. Dr. Hartmut Geiger.
“... will allow us to pursue our goal of rejuvenating aging stem cells, " said Dr. Jürgen Reess, CEO.
“We believe that MoglingBio’s technology is groundbreaking by truly rejuvenating old stem cells" – Frank Schueler, Kizoo's MD.
